The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

Liam Rose[1], Laura Graham[1], Allison Koenecke[2], Michael Powell[3], Ruoxuan Xiong[4], Zhu Shen[5], Kenneth W. Kinzler[6], Chetan Bettegowda[6,7], Bert Vogelstein[6], Maximilian F. Konig[6,8], Susan Athey[9], Joshua T. Vogelstein[3,10], Todd H. Wagner[1,11*]

[1]VA Health Economics Resource Center, Palo Alto VA, Menlo Park, CA, USA

[2]Institute for Computational & Mathematical Engineering, Stanford University, Stanford, CA, USA

[3]Department of Biomedical Engineering, Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD, USA

[4]Management Science & Engineering, Stanford University, Stanford, CA, USA

[5]Department of Statistics, Stanford University, Stanford, CA, USA

[6]Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA

[7]The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[8]Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, US

[9]Stanford Graduate School of Business, Stanford University, Stanford, CA, USA

[10]Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health at Johns Hopkins University, Baltimore, MD, USA

[11]Department of Surgery, Stanford University, Stanford, CA, USA

*** Correspondence:**
Todd Wagner, VA Health Economics Resource Center, Palo Alto VA, Menlo Park, CA, USA; Department of Surgery, Stanford University, Stanford, CA, USA. Email: twagner@stanford.edu

Abstract

Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (α_1-AR antagonists) may be effective in reducing mortality related to hyperinflammation. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between use of α_1-AR antagonists at time of hospitalization and likelihood of death due to COVID-19 during an inpatient stay. Having an active prescription for an α_1-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission had a significant negative association with in-hospital mortality (relative risk reduction 14%; odds ratio 0.75; 95% CI 0.66 to 0.86; $p \leq 0.001$). These effects were also found in an expanded cohort of suspected COVID-19 patients, supporting the need for clinical trials.

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

1 Introduction

The viral replication phase in coronavirus disease 2019 (COVID-19) can be followed by a hyperinflammatory host immune response referred to as cytokine storm syndrome. This can lead to acute respiratory distress syndrome, multi-organ failure, and death despite maximal supportive care (1,2). Catecholamines amplify hyperinflammation by increasing cytokine production in immune cells (3). Alpha-1 adrenergic receptor antagonists (α_1-AR antagonists) can prevent cytokine storm syndrome and death in mice by blocking catecholamine signaling (4). In a retrospective analysis of hospitalized patients presenting with acute respiratory distress or pneumonia, patients incidentally taking α_1-AR antagonists had a 34% relative risk reduction for being mechanically ventilated and dying compared to non-users (5).

The objective of this study was to examine the association of α_1-AR antagonist use with in-hospital mortality in patients with COVID-19. We analyzed patients hospitalized at Veterans Health Administration (VA) hospitals, where α_1-AR antagonists are commonly used to treat benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), and hypertension. We hypothesized that patients with COVID-19 taking α_1-AR antagonists at the time of hospital admission would be less likely to die during their hospitalization.

2 Method

2.1 Study Population & Variables

We included all patients admitted to a VA hospital between February 20, 2020, and August 5, 2020 with a confirmed COVID-19 diagnosis (Figure 1). Diagnosis codes for COVID-19 were identified from the Centers for Disease Control and Prevention (CDC) coding guidelines for COVID-19 (6,7). The VA COVID-19 Shared Data Resource was used to identify VA patients with a SARS-CoV-2 laboratory test result (8). This data resource combines VA-specific lab results with non-VA lab results using text extraction from patient medical records. Because over 90% of α_1-AR antagonist users in the analysis were older men, we excluded women to reduce unmeasured confounding in risk of respiratory conditions unrelated to COVID-19. We also excluded patients under age 45 and patients over age 85 given the strong relationship between the severity of COVID-19 and age.

An expanded sample included all patients with laboratory-confirmed, “suspected positive”, or “possible positive” COVID-19 according to National COVID Cohort Collaborative (N3C) criteria (9). This Suspected COVID-19 sample excluded patients who tested negative for COVID-19. This cohort was not operationally different from the main cohort on vital signs at admission (Supplementary Figure 1).

The primary outcome was death during the index hospitalization. The primary exposure variable was the use of α_1-AR antagonists at the time of admission for the index hospitalization. Active prescriptions of α_1-AR antagonists (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) were identified and defined by the patient having medication on hand on the day of the index admission, regardless of dosage. Secondary analyses examined the effect of tamsulosin (the most commonly prescribed α_1-AR antagonist) and doxazosin (a nonselective α_1-AR antagonist) alone. Finally, with in-hospital therapies in-flux during the early stage of the pandemic, we repeated the analysis by week and VA hospital to ensure results were not driven by any particular time or location.

We obtained data on patient demographics, vital signs, and prescriptions from VA's corporate data warehouse (CDW). Patient comorbidities were based on the International Classification of Diseases, Version 10 codes from VA care in the prior year. Other physiologic variables, including oxygen saturation and temperature, were defined at time of inpatient admission.

2.2 Analysis

Analyses followed the methodology of a companion paper examining patients with acute respiratory distress and pneumonia (5). Unadjusted analysis compared patients with α_1-AR antagonist prescriptions to all other patients with COVID-19 using Fisher's exact test. We then estimated propensity scores and trimmed the sample to ensure overlap in the propensity score distributions of the exposed and unexposed groups. On this reduced sample, the adjusted analysis used inverse propensity-weighted logistic regression adjusting for the patient age at admission (input as a demeaned cubic polynomial to allow a nonlinear relationship), calendar week, location of hospitalization, and comorbidities diagnosed any time in the two years prior to the index inpatient stay. This approach is "doubly robust" in that it uses the observed confounders in both the calculation of the propensity score and the odds ratios. Comorbidities included in the matching procedure were diabetes, hypertension, heart failure, ischemic heart disease, acute myocardial infarction, COPD, and PTSD.

All of the control variables reflect information on the Veterans prior to admission with COVID-19. As noted above, we controlled for secular changes in COVID-19 care using calendar week, starting with February 20, 2020. We chose not to examine endpoints during the hospital stay, such as use of a ventilator or admission to the ICU, given this is based on physician coding or data structures that we cannot assure were handled uniformly, especially during surges. We also chose not to control for processes of care during the stay given this could introduce bias in the analysis.

We then conducted a 5:1 matched analysis using the same covariates as the adjusted model (10). This approach assigns each exposed patient to a set of five unexposed patients most similar on observed characteristics and does not make assumptions about the functional form of the potential relationship between confounders and the outcome. Matches were selected using a greedy, nearest-neighbor approach based on Mahalanobis distance (11). The matched analysis used the Cochran-Mantel-Haenszel test to obtain odds ratios, confidence intervals, and p-values. We also present relative risk reductions (RRR) for the matched cohorts, and the pre- and post-matching balance of covariates is shown in Figure 3.

3 Results

3.1 Sample Characteristics

The sample contained 12,266 patients with COVID-19, with 2,555 taking any α_1-AR antagonist at admission. Of those taking α_1-AR antagonists, 72% were on tamsulosin, and 4% were on doxazosin (Figure 1). Table 1 provides sample characteristics.

3.2 Risk of In-Hospital Mortality

For patients admitted to a VA hospital between February 20, 2020, and August 5, 2020, the overall in-hospital mortality rate was 9%. Among patients with confirmed COVID-19 (5.5% of all admissions), in-hospital mortality was 17.3%. Patients with COVID-19 taking any α_1-AR antagonist, compared to non-users, had a 14% relative risk reduction for death (340/2,417 in matched treatment group vs. 1,383/8,422 in matched control group, $p \leq 0.001$).

The top panel in figure 2 shows the unadjusted, propensity score adjusted, and matched odds ratios among patients diagnosed with COVID-19 (n = 12,266). The bottom panel expands the denominator to include suspected positive cases (n = 16,866). The dark green odds ratios in Figure 2 represent all α_1-AR antagonists, while the lighter green represent doxazosin. Figure 2 shows that the results are similar for the Suspected COVID-19 sample. Patients taking α_1-AR antagonists, compared to non-users, had an 11% relative risk reduction for death ($p \leq 0.001$) in this cohort (Figure 2).

Use of doxazosin, a nonselective α_1-AR antagonist similar to prazosin used in preclinical studies of cytokine storm syndrome, resulted in a 43% relative risk reduction for death (11/101 in matched treatment group vs. 96/505 in matched control group, p=0.02, Figure 2). Use of tamsulosin, the most common α_1-AR antagonist in this cohort, had a 10% relative risk reduction for death (p = 0.01, Supplementary Figure 2). Even though COVID-19 has affected different parts of the US at different times, we found no evidence that these results were driven by any particular time period or location (Supplementary Figures 3 and 4).

4 Discussion

In this retrospective analysis of patients with confirmed and suspected COVID-19, we found a significant negative association between the use of α_1-AR antagonists and in-hospital mortality. Immune cells can express all α_1-AR subtypes (α_{1A}-, α_{1D}-, and α_{1B}-AR), and catecholamine signaling through individual receptors may be highly redundant (1,2). Emerging preclinical data suggests that α_1-AR antagonists with nonselective effects on α_{1A}-, α_{1D}-, and α_{1B}-AR may be potent in mitigating hyperinflammation and preventing death in animal models of cytokine storm syndrome (3). In patients with suspected COVID-19, use of doxazosin, an antagonist on all three α_1-ARs, was associated with significantly reduced in-hospital mortality compared to controls (odds ratio for death 0.38 in adjusted and 0.51 in matched cohorts). A similar trend was seen in patients with confirmed COVID-19, but the sample size limited precision. Tamsulosin, by comparison, is a "uroselective" α_1-AR antagonist with antagonism on both α_{1A}- and α_{1D}-ARs expressed in prostatic tissue, without clinically relevant inhibition of α_{1B}-ARs expressed by immune cells and peripheral vasculature. Baseline tamsulosin use in patients with confirmed and suspected COVID-19 was associated with significant, but less pronounced reductions in in-hospital mortality (Supplementary Figure 2), consistent with a potential redundancy in catecholamine signaling through the α_{1B}-AR (12).

One concern with observational analysis is confounding by indication, especially if medication use is correlated with disease severity. This analysis examines Veterans' use of α_1-AR antagonists prior to hospitalization. These medications are often used to manage chronic conditions, and prescribing practices would not be biased by the severity of COVID-19. In addition, the results were not driven by a specific location or time period.

This study has some important strengths and weaknesses. A strength is the focus on mortality thereby avoiding process measures, such as use of ventilators or admission to an ICU, that could be biased if clinicians or hospitals changed their practices in unobserved ways. Another strength is our use of information prior to the COVID-19 admission for risk adjustment. We also did not control for process of care during the stay, which might induce biases. One limitation in this study was the exclusion of women because α_1-AR antagonists are most commonly used to treat benign prostatic hyperplasia, and 90% of patients in the VA system are men (13). A second limitation was our inability to examine dose effects given our sample size. These issues would need to be evaluated in a prospective clinical trial.

The results highlight the need for prospective, controlled clinical trials to examine the efficacy of doxazosin for reducing in-hospital mortality and other adverse outcomes from COVID-19. α_1-AR antagonists are inexpensive, administered orally, and have an established safety profile. Thus, if trials confirm these results, α_1-AR antagonists could be widely deployed. Prior research has shown that α_1-AR antagonists were associated with fewer adverse outcomes for patients with pneumonia (5)**,** so a clinical trial might reveal options for mitigating the cytokine storm resulting from pneumonia, COVID-19, or another coronavirus.

In summary, this study suggests that male patients with laboratory-confirmed, "suspected positive", or "possible positive" COVID-19 diagnosis had lower odds of mortality if they had an active prescription for an α_1-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission (relative risk reduction 14%). There was considerable variation by type of α_1-AR antagonist. Doxazosin was associated with 43% relative risk reduction for death, while tamsulosin, the most common α_1-AR antagonist in this cohort, had a 10% relative risk reduction for death. A clinical trial testing the efficacy of an α_1-AR antagonist, most likely doxazosin, would appear warranted.

5 Conflict of Interest

In 2017, The Johns Hopkins University (JHU) filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which VS, RB, NP, BV, KWK, and SZ are listed as inventors. JHU will not assert patent rights from this filing for treatment related to COVID-19. MFK received personal fees from Bristol-Myers Squibb and Celltrion. BV, KWK, and NP are founders of and hold equity in Thrive Earlier Detection. KWK and NP are consultants to and are on the Board of Directors of Thrive Earlier Detection. BV, KWK, NP, and SZ are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. SZ holds equity in Thrive Earlier Detection and has a research agreement with BioMed Valley Discoveries, Inc. KWK and BV are consultants to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. NP is an advisor to and holds equity in Cage Pharma. BV is also a consultant to Nexus. KWK, BV, SZ, and NP are consultants to and hold equity in NeoPhore. CB is a consultant to Depuy-Synthes and Bionaut Pharmaceuticals. CB, BV, KWK, and NP are also inventors on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies. SA is an advisor and holds an equity stake in two private companies, Prealize (Palo Alto, California, USA) and Dr. Consulta (Brazil). Prealize is a health care analytics company, and Dr. Consulta operates a chain of low-cost medical clinics in Brazil.

Author Contributions

JV, BV, CB, and MK conceived of the precented idea. LR, LG, AK, MP, and RX conducted statistical analyses and results presentation. AK, MP, RX, ZS, and SA developed the methodology. LR, JV, TW wrote the manuscript with input from all authors. All authors reviewed the final manuscript.

6 Funding

The work of Allison Koenecke is supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE – 1656518. Dr. Konig was supported by the National

Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award no. T32AR048522. Dr. Bettegowda was supported by the Burroughs Wellcome Career Award for Medical Scientists. Dr. Athey was supported by the Office of Naval Research under Grant N00014-17-1-2131. This work was further supported by The Virginia and D.K. Ludwig Fund for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer Research, the BKI Cancer Genetics and Genomics Research Program. Dr. Wagner was funded by a VA Research Career Scientist Award (RCS-17-154). Research, including data analysis, was partially supported by funding from Microsoft Research and Fast Grants, part of the Emergent Ventures Program at The Mercatus Center at George Mason University.

7 Acknowledgments

Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Department of Veterans Affairs or the National Science Foundation.

This project was sponsored by the VA Office of Reporting, Analytics, Performance, Improvement and Deployment, and the VA Center for Medication Safety, and approved as quality improvement by the Stanford University Institutional Review Board.

References

1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* (2020)

2. Konig MF, Powell M, Staedtke V, Bai R-Y, Thomas DL, Fischer N, Huq S, Khalafallah AM, Koenecke A, Xiong R, et al. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. *J Clin Invest* (2020) 130:3345–3347.

3. Heijnen CJ, van der Voort CR, Wulffraat N, van der Net J, Kuis W, Kavelaars A. Functional α1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. *J Neuroimmunol* (1996) 71:223–226.

4. Staedtke V, Bai R-Y, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. *Nature* (2018) 564:273–277.

5. Koenecke A, Powell M, Xiong R, Shen Z, Fischer N, Huq S, Khalafallah AM, Trevisan M, Sparen P, Carrero JJ, et al. Alpha-1 adrenergic receptor antagonists to prevent acute respiratory distress syndrome and death from cytokine storm syndrome. (2020)

6. CDC. *ICD-10-CM official coding guidance interim advice for cornavirus Feb 20, 2020*.

7. CDC. *ICD-10-CM official coding and reporting guidleines COVID-19 Guidelines April 1, 2020 through September 30, 2020*.

8. Department of Veterans Affairs COVID-19 National Summary. Available at: https://www.accesstocare.va.gov/Healthcare/COVID19NationalSummary

9. National Center for Advancing Translational Sciences. *National COVID Cohort Collaborative Phenotype Data Acquisition*. Available at: https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype

10. Stuart EA. Matching methods for causal inference: A review and a look forward. *Stat Sci* (2010) 25:1–21.

11. Ho D, Imai K, King G, Stuart E. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. *Journal of Statistical Software, Articles* (2011) 42:1–28.

12. Grisanti LA, Woster AP, Dahlman J, Sauter ER, Combs CK, Porter JE. α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. *J Pharmacol Exp Ther* (2011) 338:648–657.

13. US Department of Veterans Affairs, Veterans Health Administration. *The Changing Face of Women Veterans*. Available at: https://www.womenshealth.va.gov/WOMENSHEALTH/latestinformation/facts.asp

Table 1: Patient and sample characteristics at time of admission

	Control (n = 9,711)	α1-AR antagonist (n = 2,555)	Overall (n = 12,266)
Age			
Mean (SD)	67.4 (9.22)	70.6 (7.94)	68.1 (9.07)
Median [Min, Max]	69.0 [45.0, 85.0]	72.0 [45.0, 85.0]	70.0 [45.0, 85.0]
Comorbidities in the prior year			
Hypertension: n (%)	7782 (80.1%)	2273 (89.0%)	10055 (82.0%)
CAD: n (%)	398 (4.1%)	137 (5.4%)	535 (4.4%)
CHF: n (%)	2983 (30.7%)	882 (34.5%)	3865 (31.5%)
COPD: n (%)	3364 (34.6%)	1138 (44.5%)	4502 (36.7%)
Diabetes: n (%)	5121 (52.7%)	1492 (58.4%)	6613 (53.9%)
MI: n (%)	763 (7.9%)	224 (8.8%)	987 (8.0%)
BPH: n (%)	2564 (26.4%)	2002 (78.4%)	4566 (37.2%)
PTSD: n (%)	2042 (21.0%)	765 (29.9%)	2807 (22.9%)
VA Hospital			
508 (Atlanta)	216 (2.2%)	61 (2.4%)	277 (2.3%)
549 (Dallas)	191 (2.0%)	55 (2.2%)	246 (2.0%)
573 (Gainesville, FL)	180 (1.9%)	69 (2.7%)	249 (2.0%)
580 (Houston)	279 (2.9%)	93 (3.6%)	372 (3.0%)
589 (Kansas City)	194 (2.0%)	70 (2.7%)	264 (2.2%)
614 (Memphis)	441 (4.5%)	138 (5.4%)	579 (4.7%)
630 (New York Harbor)	365 (3.8%)	79 (3.1%)	444 (3.6%)
644 (Phoenix)	260 (2.7%)	53 (2.1%)	313 (2.6%)
671 (San Antonio)	296 (3.0%)	70 (2.7%)	366 (3.0%)
673 (Tampa)	209 (2.2%)	47 (1.8%)	256 (2.1%)
Other VA hospitals	7080 (72.9%)	1820 (71.2%)	8900 (72.6%)

Note: CAD = coronary artery disease, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, MI = acute myocardial infarction, BPH = benign prostatic hyperplasia, PTSD = post-traumatic stress disorder. PTSD was excluded from the adjusted analysis due to collinearity with other comorbidities. Listed VA hospitals had the most COVID-19 inpatient hospitalizations during the study period.

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

Figure 1. CONSORT flow diagram



Figure 2. Adjusted Odds of In-hospital Mortality and Use of α1-AR Antagonists at Time of Admission



Figure 2. Hospitalized patients diagnosed with COVID-19 (top) and with diagnosed or suspected COVID-19 (bottom). Forest plot showing odds ratios of in-hospital mortality based on prior use of any alpha-1 adrenergic receptor antagonists (dark green) or doxazosin (light green). Relative risk reduction (RRR), odds ratios (OR) for death, confidence intervals (CI), and p-values (for unadjusted, adjusted, and matched models), and sample size (n) for each analysis are shown on the right.

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

Figure 3. Standardized mean differences in patient characteristics before and after matching for both the diagnosed (A) and suspected (B) cohorts



The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

Supplementary Figure 1. Vital signs at admission for main analysis cohort of patients diagnosed with COVID-19 and an expanded cohort of patients suspected to have COVID-19

Measure	Diagnosed COVID-19	Suspected COVID-19	Difference
O2 Sat <90%	0.043	0.048	-0.005
Average O2 Sat	95.602	95.519	0.083
Average Temperature	98.419	98.368	0.051

Supplementary Figure 1. Vital signs on admission for the main cohort ("Diagnosed COVID-19") and the broad cohort used in the supplementary analysis ("Suspected COVID-19). Smoothed lines are from a loess model with 95% confidence intervals shown (gray ribbons).

Supplementary Figure 2. Adjusted Odds of In-hospital Mortality and Use of α_1-AR Antagonists at Time of Admission, Tamsulosin



Supplementary Figure 2. Hospitalized patients with confirmed COVID-19 (top) and suspected COVID-19 (bottom). Forest plot showing odds ratios of in-hospital mortality based on prior use of any alpha-1 adrenergic receptor antagonists or tamsulosin (left). Relative risk reduction (RRR), odds ratios (OR) for death, confidence intervals (CI), p-values (for unadjusted, adjusted, and matched models), and sample size (n) for each analysis are shown on the right.

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

Supplementary Figure 3: Adjusted Odds of In-hospital Mortality and Use of α_1-AR Antagonists by Week



Supplementary Figure 3: Adjusted odds of in-hospital mortality and use of α_1-AR Antagonists by week of admission (top) and count of new admission admissions by week and use of α_1-AR Antagonists (bottom) meant to capture variation in treatment practices over time. Top panel truncated between 0 and 2 to aid visualization.

Supplementary Figure 4. Adjusted Odds of In-hospital Mortality and Use of α_1-AR Antagonists by VA Station



Supplementary Figure 4: Adjusted odds of in-hospital mortality and use of α_1-AR Antagonists by station of admission (top) and count of new admission admissions by VA station and use of α_1-AR antagonists (bottom) meant to capture variation in treatment practice over location. Top panel truncated between 0 and 2 to aid visualization. The count of other VA stations was 7,645 admissions of patients not using α_1-AR antagonists and 1,845 admissions of patients using α_1-AR Antagonists. VA stations shown: 508 = Atlanta, 549 = Dallas, 573 = Gainesville, 580 = Houston, 589 = Kansas City, 614 = Memphis, 630 = New York Harbor, 644 = Phoenix, 671 = San Antonio, 673 = Tampa.